|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.92 USD | +2.23% |
|
-1.90% | +13.44% |
| 03:48am | Glenmark Pharmaceuticals to Launch Leucovorin Calcium for Injection | MT |
| 12-08 | Halozyme Therapeutics, Inc. Announces Election of Jim Lang to Board of Directors, Effective December 4, 2025 | CI |
| Capitalization | 37.96B 32.6B 30.48B 28.48B 52.54B 3,412B 57.17B 353B 138B 1,617B 142B 139B 5,936B | P/E ratio 2025 * |
31.4x | P/E ratio 2026 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise value | 51.33B 44.07B 41.22B 38.5B 71.04B 4,614B 77.3B 478B 186B 2,187B 193B 189B 8,026B | EV / Sales 2025 * |
3.17x | EV / Sales 2026 * | 2.97x |
| Free-Float |
67.55% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Iqvia Holdings Inc.
| 1 day | +2.23% | ||
| 1 week | -1.90% | ||
| Current month | -3.08% | ||
| 1 month | +4.63% | ||
| 3 months | +21.24% | ||
| 6 months | +39.53% | ||
| Current year | +13.44% |
| 1 week | 217.86 |  | 226.64 |
| 1 month | 213.9 | | 234.3 |
| Current year | 134.64 | | 234.3 |
| 1 year | 134.64 | | 234.3 |
| 3 years | 134.64 | | 261.73 |
| 5 years | 134.64 | | 285.61 |
| 10 years | 55.01 | | 285.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 64 | 02/10/2016 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 64 | 31/07/2020 |
Jeffrey Spaeder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
John Leonard
BRD | Director/Board Member | 67 | 04/02/2015 |
John Connaughton
BRD | Director/Board Member | 59 | 31/12/2007 |
Ari Bousbib
CHM | Chairman | 64 | 02/10/2016 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.92% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.23% | -1.90% | +9.70% | +6.90% | 37.96B | |
| -0.70% | -2.85% | +2.79% | +17.60% | 47.04B | |
| +1.25% | -4.49% | +72.10% | +63.80% | 35.71B | |
| -0.85% | +1.31% | +11.36% | +16.84% | 27.64B | |
| +3.06% | -2.73% | +63.99% | +172.51% | 15.8B | |
| +0.09% | +0.24% | +64.69% | +227.50% | 15.06B | |
| +2.52% | -1.02% | -13.94% | -4.57% | 14.19B | |
| -1.07% | +0.21% | +66.82% | - | 13.36B | |
| -0.29% | -3.92% | +105.51% | +109.68% | 12.74B | |
| +2.34% | +0.37% | +55.19% | +71.90% | 12.3B | |
| Average | +1.12% | -1.44% | +43.82% | +75.80% | 23.18B | |
| Weighted average by Cap. | +0.88% | -1.80% | +34.90% | +55.85% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 16.19B 13.9B 13B 12.14B 22.41B 1,455B 24.38B 151B 58.73B 690B 60.75B 59.46B 2,531B | 17.06B 14.65B 13.7B 12.8B 23.61B 1,533B 25.69B 159B 61.89B 727B 64.02B 62.66B 2,668B |
| Net income | 1.23B 1.06B 992M 926M 1.71B 111B 1.86B 11.5B 4.48B 52.61B 4.63B 4.54B 193B | 1.45B 1.25B 1.17B 1.09B 2.01B 130B 2.19B 13.51B 5.27B 61.84B 5.45B 5.33B 227B |
| Net Debt | 13.37B 11.48B 10.73B 10.03B 18.5B 1,201B 20.13B 124B 48.49B 569B 50.15B 49.09B 2,090B | 12.68B 10.89B 10.18B 9.51B 17.55B 1,140B 19.09B 118B 46B 540B 47.58B 46.57B 1,982B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/25 | 222.92 $ | +2.23% | 1,458,875 |
| 09/12/25 | 218.06 $ | -2.46% | 1,185,496 |
| 08/12/25 | 223.57 $ | -1.01% | 1,269,946 |
| 05/12/25 | 225.85 $ | +0.41% | 1,690,026 |
| 04/12/25 | 224.92 $ | -1.02% | 3,298,872 |
Delayed Quote Nyse, December 10, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IQV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition